ClinicalTrials.gg
TerminatedNCT02353754Updated Mar 26, 2021Results posted

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

A Phase 4 interventional study of Intrathecal morphine injection and EXPAREL in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Why this study was terminated
Slow enrollment. None of the subjects received EXPAREL.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.

Enrollment
30th of 36
12 · median 60
Started
2015
with 5 others
Phase 4
22 of 36
2 open now
Registered
12th of 36
by date
Lead sponsor
7 of 36
Pacira Pharmaceuticals, Inc

Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 30th largest by enrollment, is one of 6 that started in 2015, is one of 22 in phase 4, and was the 12th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Liposomal Bupivacaine in Pain, or all of them as a file.
02

Study summary

This is a Phase 4, multicenter, open-label study evaluating EXPAREL infiltration into the transversus abdominis plane (TAP) after bupivacaine hydrochloride (HCl) spinal anesthesia in subjects undergoing elective Cesarean section (C-section).

Read the detailed description

There will be two groups of subjects with approximately 40 subjects per group. Prior to the C-section, all subjects will receive single-shot spinal anesthesia (1.5 mL bupivacaine HCl 0.75% with dextrose 8.25%). Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered. Subjects in Group 2 (EXPAREL/TAP) will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females ≥18 years of age at screening.
  2. Scheduled to undergo elective C-section (single or multiple births).
  3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.
  4. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. History of or idiosyncratic reaction to amide-type local anesthetics or opioids.
  2. to bupivacaine, morphine, ketorolac, ibuprofen, or acetaminophen.
  3. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.
  4. Use of any of the following medications within the times specified before surgery: long-acting opioid medication, non-steroidal anti-inflammatory drugs (NSAIDs), or aspirin (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid medication or acetaminophen within 24 hours.
  5. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, she must be on a stable dose for at least 1 month prior to study drug administration.
  6. medical or psychiatric disease that, in the opinion of the Investigator, would constitute a contraindication to participation in the study or cause inability to comply with the study requirements.
  7. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medication(s), or alcohol within the past 2 years.
  8. Received an drug within 30 days prior to study drug administration, and/or has planned administration of another investigational product or procedure while participating in this study.
  9. Previous participating in an EXPAREL study.

    The subject will be withdrawn from the study if she meets the following criteria:

  10. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course.
  11. Her baby's 5-minute Apgar score is ≤7.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Standard of Care

    Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.

    Drug: Intrathecal morphine injection

  • Experimental
    EXPAREL/TAP

    Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).

    Drug: EXPAREL

Interventions

06

What researchers measure

Primary outcomes

  1. Total Postsurgical Narcotic Consumption in Morphine Equivalents

    Outcome measure data refer to 7 participants who received rescue medication

    Time frame: Through 72 hours postdose

Secondary outcomes

  1. Total Postsurgical Narcotic Consumption in Morphine Equivalents

    Outcome measure data refer to 6 participants who received rescue medication

    Time frame: Through 24 hours

  2. Total Postsurgical Narcotic Consumption in Morphine Equivalents

    Outcome measure data refer to 7 participants who received rescue medication

    Time frame: Through 48 hours

07

Results

Posted Jun 28, 2016

Participant flow

Participant flow — Overall Study
MilestoneStandard of CareEXPAREL/TAP
Started120
Completed100
Not completed20

Outcome measures

PrimaryTotal Postsurgical Narcotic Consumption in Morphine Equivalents

Outcome measure data refer to 7 participants who received rescue medication

Time frame:
Through 72 hours postdose
Reported as:
Mean · MUEs
Total Postsurgical Narcotic Consumption in Morphine Equivalents
MUEsStandard of CareEXPAREL/TAP
Total Postsurgical Narcotic Consumption in Morphine Equivalents6.1 ± 3.67—
SecondaryTotal Postsurgical Narcotic Consumption in Morphine Equivalents

Outcome measure data refer to 6 participants who received rescue medication

Time frame:
Through 24 hours
Reported as:
Mean · MUEs
Total Postsurgical Narcotic Consumption in Morphine Equivalents
MUEsStandard of CareEXPAREL/TAP
Total Postsurgical Narcotic Consumption in Morphine Equivalents4.9 ± 2.01—
SecondaryTotal Postsurgical Narcotic Consumption in Morphine Equivalents

Outcome measure data refer to 7 participants who received rescue medication

Time frame:
Through 48 hours
Reported as:
Mean · MUEs
Total Postsurgical Narcotic Consumption in Morphine Equivalents
MUEsStandard of CareEXPAREL/TAP
Total Postsurgical Narcotic Consumption in Morphine Equivalents6.1 ± 3.67—

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care—0/12 (0%)2/12 (16.7%)
EXPAREL/TAP———
Most frequent other events
Most frequent other events
EventStandard of CareEXPAREL/TAP
oral herpesInfections and infestations1/12—
bladder injuryInjury, poisoning and procedural complications1/12—

Baseline characteristics

The study was terminated due to slow enrollment after 12 subjects were assigned to Group 1 (Standard of Care/Duramorph). As no subjects were enrolled into Group 2 (EXPAREL/TAP), no conclusions can be drawn regarding the study endpoints.

Age, Categorical
Age, Categorical(Participants)Standard of CareEXPAREL/TAPTotal
<=18 years0—0
Between 18 and 65 years12—12
>=65 years0—0
Age, Continuous
Age, Continuous(years)Standard of CareEXPAREL/TAPTotal
Mean32.2 ± 4.71—32.2 ± 4.71
Sex/Gender, Customized
Sex/Gender, Customized(participants)Standard of CareEXPAREL/TAPTotal
Female12—12
Male0—0
Region of Enrollment
Region of Enrollment(participants)Standard of CareEXPAREL/TAPTotal
United States12—12
08

Study locations

5 sites
  • Tradition Medical Center
    Port Saint Lucie, Florida 34987, United States
  • University Of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Saint Peter's University Hospital
    New Brunswick, New Jersey 08901, United States
  • Montefiore
    Bronx, New York 10467, United States
  • The Ohio State University, Wexner Medical Center
    Columbus, Ohio 43210, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jun 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2015
First posted
Feb 3, 2015
Start
May 2015
Primary completionActual
Jun 2015
CompletionActual
Jul 2015
Results first posted
Jun 28, 2016
Last update
Mar 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02353754
Responsible party
Sponsor
First posted
Feb 3, 2015
Start date
May 2015
Primary completion
Jun 2015
Completion
Jul 2015
Results posted
Jun 28, 2016
Last update
Mar 26, 2021

Study contacts

Erol Onel, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion